Carcinoid syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{{Carcinoid syndrome}} {{CMG}} ==Overview== ==Chemotherapy== Chemotherapy is of little benefit and is generally not indicated. Octreotide (a somatostatin analogu...") |
No edit summary |
||
Line 3: | Line 3: | ||
==Overview== | ==Overview== | ||
For symptomatic relief of carcinoid sydromes medical therapy many include: [[octreotide]], [[methysergide maleate]], and [[cyproheptadine]]. | |||
==Medical Therapy== | |||
Symptomatic relief may be provided by any of the following medical therapies: | |||
*Octreotide (somatostatin analogue- neutralizes serotonin and decreases urinary 5-HIAA) | |||
*Methysergide maleate (antiserotonin agent but not used because of serious side effect of retroperitoneal fibrosis) | |||
*Cyproheptadine ([[antihistamine]]) | |||
==Chemotherapy== | ==Chemotherapy== |
Revision as of 19:40, 6 August 2012
Carcinoid syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Carcinoid syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Carcinoid syndrome medical therapy |
Risk calculators and risk factors for Carcinoid syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
For symptomatic relief of carcinoid sydromes medical therapy many include: octreotide, methysergide maleate, and cyproheptadine.
Medical Therapy
Symptomatic relief may be provided by any of the following medical therapies:
- Octreotide (somatostatin analogue- neutralizes serotonin and decreases urinary 5-HIAA)
- Methysergide maleate (antiserotonin agent but not used because of serious side effect of retroperitoneal fibrosis)
- Cyproheptadine (antihistamine)
Chemotherapy
Chemotherapy is of little benefit and is generally not indicated. Octreotide (a somatostatin analogue) may decrease the secretory activity of the carcinoid.